More than a simple storage organ: Adipose tissue as a source of adipokines involved in cardiovascular disease

Thrombosis and Haemostasis

Volumn 110, Issue 4, 2013, Pages 641-650

  Rega Kaun, Gersina ^a,b   Kaun, Christoph ^a   Wojta, Johann ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Wilhelminenspital   (Austria)

^c Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

Atherosclerosis; Obesity; Thrombosis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN A1C; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; LEUKEMIA INHIBITORY FACTOR; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEBIVOLOL; OSTEOPONTIN; PIGMENT EPITHELIUM DERIVED FACTOR; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; ROSIGLITAZONE; TOLL LIKE RECEPTOR 4; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL MIGRATION; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART INFARCTION; HUMAN; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WEIGHT REDUCTION;

ATHEROSCLEROSIS; OBESITY; THROMBOSIS;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; OBESITY;

EID: 84884869486     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-03-0212     Document Type: Article

References (150)

1. Must A, et al. The disease burden associated with overweight and obesity. J Am Med Assoc 1999; 282: 1523-1529.
2. Pischon T, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120.
3. Swinburn BA, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011; 378: 804-814.
4. Finkelstein EA, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med 2012; 42: 563-570.
5. Go AS, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-e245.
6. Adams TD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753-761.
7. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97: 2482-2488.
8. Bluher M. Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes 2012; 19: 341-346.
9. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 2005; 64: 163-169.
10. Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009; 117: 241-250.
11. Skurk T, et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-1033.
12. Arita Y, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
13. Bruun JM, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-533.
14. Gregoire FM. Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol Med 2001; 226: 997-1002.
15. Guo X, Liao K. Analysis of gene expression profile during 3T3-L1 preadipocyte differentiation. Gene 2000; 251: 45-53.
16. Fain JN, et al. Comparison of the release of adipokines by adipose tissue, adi-pose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-2282.
17. Cinti S, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46: 2347-2355.
18. Lumeng CN, et al. Obesity induces a phenotypic switch in adipose tissue macro-phage polarization. J Clin Invest 2007; 117: 175-184.
19. Zeyda M, et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes 2007; 31: 1420-1428.
20. Morris DL, et al. Adipose tissue macrophages: phenotypic plasticity and diver- sity in lean and obese states. Curr Opin Clin Nutr Metab Care 2011; 14: 341-346.
21. Harford KA, et al. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc 2011;70: 408-417.
22. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
23. Dasu MR, Jialal I. Free Fatty Acids in the presence of High Glucose Amplify Monocyte Inflammation via Toll-like Receptors. Am J Physiol Endocrinol Metab 2011; 300: E145-154.
24. Nguyen MT, et al. A subpopulation of macrophages infiltrates hypertrophic adi-pose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282: 35279-35292.
25. Ye J, et al. Hypoxia is a potential risk factor for chronic inflammation and adipo-nectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Phy- siol Endocrinol Metab 2007; 293: E1118-1128.
26. Klein S, et al. Absence of an effect of liposuction on insulin action and risk fac- tors for coronary heart disease. N Engl J Med 2004; 350: 2549-2557.
27. Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: experi-ences from the SOS study. Int J Obes 2008; 32 (Suppl 7): S93-97.
28. Cancello R, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005; 54: 2277-2286.
29. Zhang Y, et al. Positional cloning of the mouse obese gene and its human homo-logue. Nature 1994; 372: 425-432.
30. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
31. Ramachandrappa S, Farooqi IS. Genetic approaches to understanding human obesity. J Clin Invest 2011; 121: 2080-2086.
32. Farooqi IS, et al. Clinical and molecular genetic spectrum of congenital defi- ciency of the leptin receptor. N Engl J Med 2007; 356: 237-247.
33. Maffei M, et al. Leptin levels in human and rodent: measurement of plasma lep- tin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1:1155-1161.
34. Heymsfield SB, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J Am Med Assoc 1999;282: 1568-1575.
35. Moon HS, et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 2011; 60:1647-1656.
36. Vatier C, et al. Therapeutic use of recombinant methionyl human leptin. Bio- chimie 2012; 94: 2116-2125.
37. Montague CT, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 1998; 47: 1384-1391.
38. Guo KY, et al. Effects of obesity on the relationship of leptin mRNA expression and adipocyte size in anatomically distinct fat depots in mice. Am J Physiol Regul Integr Comp Physiol 2004; 287: R112-119.
39. Lonnqvist F, et al. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 1997; 99: 2398-2404.
40. Lofgren P, et al. Long-term prospective and controlled studies demonstrate adi-pose tissue hypercellularity and relative leptin deficiency in the postobese state. J Clin Endocrinol Metab 2005; 90: 6207-6213.
41. Wang B, et al. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadi-pocytes. J Endocrinol 2008; 198: 127-134.
42. Gualillo O, et al. Elevated serum leptin concentrations induced by experimental acute inflammation. Life Sci 2000; 67: 2433-2441.
43. Luheshi GN, et al. Leptin actions on food intake and body temperature are me- diated by IL-1. Proc Natl Acad Sci USA 1999; 96: 7047-7052.
44. Curat CA, et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004; 53:1285-1292.
45. Gruen ML, et al. Leptin requires canonical migratory signalling pathways for in-duction of monocyte and macrophage chemotaxis. Am J Physiol Cell Physiol 2007; 293: C1481-1488.
46. Northcott JM, et al. Adipokines and the cardiovascular system: mechanisms mediating health and disease. Can J Physiol Pharmacol 2012; 90: 1029-1059.
47. Rosenbaum M, et al. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest 2008; 118: 2583-2591.
48. Ozcan L, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 2009; 9: 35-51.
49. Kashyap SR, et al. Metabolic Effects of Bariatric Surgery in Patients With Mod-erate Obesity and Type 2 Diabetes: Analysis of a randomized control trial com-paring surgery with intensive medical treatment. Diabetes Care 2013; Epub ahead of print.
50. Hu E, et al. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703.
51. Maeda K, et al. cDNA cloning and expression of a novel adipose specific col- lagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289.
52. Yamauchi T, et al. Adiponectin stimulates glucose utilization and fatty-acid ox-idation by activating AMP-activated protein kinase. Nat Med 2002; 8:1288-1295.
53. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical impli-cations. Diabetologia 2012; 55: 2319-2326.
54. Matsunami T, et al. Regulation of synthesis and oxidation of fatty acids by adi- ponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model. Metab- olism 2011; 60: 805-814.
55. Halleux CM, et al. Secretion of adiponectin and regulation of apM1 gene ex- pression in human visceral adipose tissue. Biochem Biophys Res Commun 2001;288: 1102-1107.
56. Hector J, et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007; 39: 250-255.
57. Kubota N, et al. Disruption of adiponectin causes insulin resistance and neointi- mal formation. J Biol Chem 2002; 277: 25863-25866.
58. Matsuda M, et al. Role of adiponectin in preventing vascular stenosis. The miss- ing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487-37491.
59. Okamoto Y, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000; 32: 47-50.
60. Ouchi N, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits en- dothelial NF-kappaB signalling through a cAMP-dependent pathway. Circu-lation 2000; 102: 1296-1301.
61. Kumada M, et al. Adiponectin specifically increased tissue inhibitor of metallo- proteinase-1 through interleukin-10 expression in human macrophages. Circu-lation 2004; 109: 2046-2049.
62. Ohashi K, et al. Adiponectin promotes macrophage polarization toward an anti- inflammatory phenotype. J Biol Chem 2010; 285: 6153-6160.
63. Ouchi N, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063.
64. Pischon T, et al. Plasma adiponectin levels and risk of myocardial infarction in men. J Am Med Assoc 2004; 291: 1730-1737.
65. Shioji K, et al. Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ J 2007; 71: 675-680.
66. Persson J, et al. Low plasma adiponectin concentration is associated with myo- cardial infarction in young individuals. J Intern Med 2010; 268: 194-205.
67. Sattar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006; 114: 623-629.
68. Pischon T, et al. Letter by Pischon et al regarding article, Adiponectin and cor- onary heart disease: a prospective study and meta-analysis. Circulation 2007;115: e322; author reply e3.
69. Yamashita T, et al. Combination of serum adiponectin level and metabolic syn- drome is closely associated with coronary artery disease in Japanese subjects with good glycemic control. Intern Med 2010; 49: 721-727.
70. Holland WL, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011; 17: 55-63.
71. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 2009; 43: 157-168.
72. Kistorp C, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762.
73. Matsumoto M, et al. Decrease in serum adiponectin levels in response to treat- ment predicts good prognosis in acute decompensated heart failure. J Clin Hy-pertens 2010; 12: 900-904.
74. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve in- sulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008; 10: 1204-1211.
75. Iwaki M, et al. Induction of adiponectin, a fat-derived antidiabetic and antiathe- rogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663.
76. Bodles AM, et al. Pioglitazone increases secretion of high-molecular-weight adi-ponectin from adipocytes. Am J Physiol Endocrinol Metab 2006; 291: E1100-1105.
77. Saremi A, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 393-399.
78. Yang HB, et al. Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance. Diabet Med 2012; 29: 359-365.
79. Sam S, et al. Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. J Clin Endocri-nol Metab 2012; 97: E110-114.
80. Shen X, et al. Pioglitazone prevents hyperglycemia induced decrease of AdipoR1 and AdipoR2 in coronary arteries and coronary VSMCs. Mol Cell Endocrinol 2012; 363: 27-35.
81. Nesto RW, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108: 2941-2948.
82. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
83. Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
84. Athyros VG, et al. Should adipokines be considered in the choice of the treat- ment of obesity-related health problems? Curr Drug Targets 2010; 11: 122-135.
85. Vaiopoulos AG, et al. The role of adiponectin in human vascular physiology. Int J Cardiol 2012; 155: 188-193.
86. Dutheil F, et al. Blood lipids and adipokines concentrations during a 6 months nutritional and physical activity intervention for metabolic syndrome treat-ment. Lipids Health Dis 2010; 9: 148.
87. Hulver MW, et al. Adiponectin is not altered with exercise training despite en- hanced insulin action. Am J Physiol Endocrinol Metab 2002; 283: E861-865.
88. Butner KL, et al. A review of weight loss following Roux-en-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin. Obes Surg 2010; 20: 559-568.
89. Komiya T, et al. Cloning of the novel gene intelectin, which is expressed in intes- tinal paneth cells in mice. Biochem Biophys Res Commun 1998; 251: 759-762.
90. Schaffler A, et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005; 1732: 96-102.
91. Yang RZ, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-1261.
92. de Souza Batista CM, et al. Omentin plasma levels and gene expression are de- creased in obesity. Diabetes 2007; 56: 1655-1661.
93. Auguet T, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011; 12: 60.
94. Jialal I, et al. Increased chemerin and decreased omentin-1 in both adipose tis- sue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab 2013;98: E514-517.
95. Liu R, et al. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011; 93: 21-25.
96. Moreno-Navarrete JM, et al. Circulating omentin as a novel biomarker of en- dothelial dysfunction. Obesity 2011; 19: 1552-1559.
97. Zhong X, et al. Omentin inhibits TNF-alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway. Biochem Biophys Res Commun 2012; 425: 401-406.
98. Shang FJ, et al. Serum omentin-1 levels are inversely associated with the pres- ence and severity of coronary artery disease in patients with metabolic syn-drome. Biomarkers 2011; 16: 657-662.
99. Shibata R, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011; 219: 811-814.
100. Yamawaki H, et al. Omentin, a novel adipocytokine inhibits TNF-induced vas- cular inflammation in human endothelial cells. Biochem Biophys Res Com-mun 2011; 408: 339-343.
101. Tan BK, et al. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010; 59: 3023-3031.
102. Shaker M, et al. Effect of Treatment with Metformin on Omentin-1, Ghrelin and other Biochemical, Clinical Features in PCOS Patients. Oman Med J 2010; 25: 289-293.
103. Esteghamati A, et al. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Regul Pept 2013; 182C: 1-6.
104. Yan P, et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 92: 368-374.
105. Saremi A, et al. Effects of aerobic training on serum omentin-1 and cardio- metabolic risk factors in overweight and obese men. J Sports Sci 2010; 28:993-998.
106. Moreno-Navarrete JM, et al. Circulating omentin concentration increases after weight loss. Nutr Metab 2010; 7: 27.
107. Scatena M, et al. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007; 27:2302-2309.
108. Matsui Y, et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:1029-1034.
109. Tousoulis D, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.Int J Cardiol 2012; Epub ahead of print.
110. Matsui Y, et al. Role of osteopontin in cardiac fibrosis and remodelling in an- giotensin II-induced cardiac hypertrophy. Hypertension 2004; 43: 1195-1201.
111. Takemoto M, et al. Enhanced expression of osteopontin by high glucose. In-volvement of osteopontin in diabetic macroangiopathy. Ann NY Acad Sci 2000; 902: 357-363.
112. Kase S, et al. Increased osteopontin levels in the vitreous of patients with dia- betic retinopathy. Ophthalmic Res 2007; 39: 143-147.
113. Nomiyama T, et al. Osteopontin mediates obesity-induced adipose tissue mac- rophage infiltration and insulin resistance in mice. J Clin Invest 2007; 117:2877-2888.
114. Gomez-Ambrosi J, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007; 92: 3719-3727.
115. Kiefer FW, et al. Osteopontin expression in human and murine obesity: exten-sive local up-regulation in adipose tissue but minimal systemic alterations. En- docrinology 2008; 149: 1350-1357.
116. Pietilainen KH, et al. Global transcript profiles of fat in monozygotic twins dis- cordant for BMI: pathways behind acquired obesity. PLoS Med 2008; 5: e51.
117. Omar B, et al. Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes-a role for the transcription factor NFAT and phosphodies-terase 3B. Biochem Biophys Res Commun 2012; 425: 812-817.
118. Ahlqvist E, et al. A link between GIP and osteopontin in adipose tissue and in- sulin resistance. Diabetes 2013; Epub ahead of print.
119. Zeyda M, et al. Osteopontin is an activator of human adipose tissue macro- phages and directly affects adipocyte function. Endocrinology 2011; 152:2219-2227.
120. Schaller G, et al. Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obes Surg 2009; 19: 351-356.
121. Riedl M, et al. Plasma osteopontin increases after bariatric surgery and corre- lates with markers of bone turnover but not with insulin resistance. J Clin En-docrinol Metab 2008; 93: 2307-2312.
122. Nakamachi T, et al. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Dia-betes 2007; 56: 1662-1670.
123. Rychli K, et al. Pigment epithelium-derived factor (PEDF) as a therapeutic tar- get in cardiovascular disease. Expert Opin Ther Targets 2009; 13: 1295-1302.
124. Famulla S, et al. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resis- tance and inflammatory signalling in muscle and fat cells. Int J Obes 2011; 35: 762-772.
125. Nakamura K, et al. Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes Metab Res Rev 2009; 25: 52-56.
126. Crowe S, et al. Pigment epithelium-derived factor contributes to insulin resis- tance in obesity. Cell Metab 2009; 10: 40-47.
127. Chen C, et al. Plasma level of pigment epithelium-derived factor is indepen- dently associated with the development of the metabolic syndrome in Chinese men: a 10-year prospective study. J Clin Endocrinol Metab 2010; 95: 5074-5081.
128. Yang S, et al. Serum pigment epithelium-derived factor is elevated in women with polycystic ovary syndrome and correlates with insulin resistance. J Clin Endocrinol Metab 2011; 96: 831-836.
129. Yamagishi S, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 2447-2450.
130. Moreno-Navarrete JM, et al. Liver, but not adipose tissue PEDF gene ex-pression is associated with insulin resistance. Int J Obes 2013; Epub ahead of print.
131. Oberbach A, et al. Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. J Proteome Res 2011; 10: 4769-4788.
132. Tschoner A, et al. Effect of weight loss on serum pigment epithelium-derived factor levels. Eur J Clin Invest 2011; 41: 937-942.
133. Ogata N, et al. Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab 2007; 92:1176-1179.
134. Chavan SS, et al. Identification of pigment epithelium-derived factor as an adi- pocyte-derived inflammatory factor. Mol Med 2012; 18: 1161-1168.
135. Tahara N, et al. Serum level of pigment epithelium-derived factor is a marker of atherosclerosis in humans. Atherosclerosis 2011; 219: 311-315.
136. Yamagishi S, et al. Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr Pharm Des 2009; 15:1027-1033.
137. Ueda S, et al. Administration of pigment epithelium-derived factor inhibits left ventricular remodelling and improves cardiac function in rats with acute myo-cardial infarction. Am J Pathol 2011; 178: 591-598.
138. Rychli K, et al. Prognostic value of pigment epithelium-derived factor in pa- tients with advanced heart failure. Chest 2010; 138: 656-664.
139. Faber DR, et al. Role of adipose tissue in haemostasis, coagulation and fibri- nolysis. Obes Rev 2009; 10: 554-563.
140. Van De Craen B, et al. The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res 2012;130: 576-585.
141. Kockx M, et al. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb Haemost 1999; 82:1490-1496.
142. Primrose JN, et al. Reduction in factor VII, fibrinogen and plasminogen acti- vator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992; 68: 396-399.
143. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207.
144. Kruszynska YT, et al. Effects of troglitazone on blood concentrations of plasmi-nogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-639.
145. Trost S, et al. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep 2006; 6: 47-54.
146. Diebold I, et al. The 'PAI-1 paradox' in vascular remodelling. Thromb Haemost 2008; 100: 984-991.
147. Crandall DL, et al. Modulation of adipose tissue development by pharmaco- logical inhibition of PAI-1. Arterioscler Thromb Vasc Biol 2006; 26: 2209-2215.
148. Alessi MC, et al. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007; 18: 240-245.
149. Rega G, et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005;111: 1938-1945.
150. Ekstrom M, et al. Stimulated in vivo synthesis of plasminogen activator in- hibitor-1 in human adipose tissue. Thromb Haemost 2012; 108: 485-492.